Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 136 articles:
HTML format
Text format



Single Articles


    March 2017
  1. PATNAIK MM, Barraco D, Lasho TL, Finke CM, et al
    Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
    Am J Hematol. 2017 Mar 17. doi: 10.1002/ajh.24722.
    PubMed     Text format     Abstract available


  2. SHORT NJ, Kantarjian HM, Ko H, Khoury JD, et al
    Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
    Am J Hematol. 2017 Mar 15. doi: 10.1002/ajh.24720.
    PubMed     Text format    


  3. MAURO FR, Galieni P, Tedeschi A, Laurenti L, et al
    Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24714.
    PubMed     Text format     Abstract available


  4. MICHALLET AS, Campidelli A, Lequeu H, Dilhuydy MS, et al
    Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France A study from the French Innovative Leukemia Organization (FILO) group.
    Am J Hematol. 2017 Mar 10. doi: 10.1002/ajh.24715.
    PubMed     Text format    


    February 2017
  5. KAYA Z, Alici N, Ozmen OE, Akgul M, et al
    Identification of renal infiltration based on urinary findings in a child with burkitt leukemia/lymphoma.
    Am J Hematol. 2017 Feb 22. doi: 10.1002/ajh.24694.
    PubMed     Text format    


  6. DE MARCHI F, Candoni A, Zannier ME, Lau WY, et al
    Concomitant monitoring of WT1 and FLT3-ITD expression in FLT3-ITD Acute Myeloid Leukemia patients: which should we trust as a minimal residual disease marker?
    Am J Hematol. 2017 Feb 17. doi: 10.1002/ajh.24686.
    PubMed     Text format    


  7. HU Z, Medeiros LJ, Fang L, Sun Y, et al
    Prognostic Significance of Cytogenetic Abnormalities in T-Cell Prolymphocytic Leukemia.
    Am J Hematol. 2017 Feb 14. doi: 10.1002/ajh.24679.
    PubMed     Text format     Abstract available


  8. USTUN C, Williams S, Skendzel S, Kodal B, et al
    Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.
    Am J Hematol. 2017 Feb 10. doi: 10.1002/ajh.24673.
    PubMed     Text format    


  9. BORATE U, Norris BA, Lo P, Tognon C, et al
    Identification of targeted therapies for rare adult mature t-cell leukemia using functional ex vivo screening of primary patient samples.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24669.
    PubMed     Text format    


  10. SHOUVAL R, Bonifazi F, Fein J, Boschini C, et al
    Validation of the Acute Leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort.
    Am J Hematol. 2017 Feb 9. doi: 10.1002/ajh.24677.
    PubMed     Text format     Abstract available


    January 2017
  11. JENTZSCH M, Bill M, Nicolet D, Leiblein S, et al
    Prognostic Impact of the CD34+/CD38- Cell Burden in Patients with Acute Myeloid Leukemia receiving Allogeneic Stem Cell Transplantation.
    Am J Hematol. 2017 Jan 30. doi: 10.1002/ajh.24663.
    PubMed     Text format     Abstract available


  12. DELGADO J, Doubek M, Baumann T, Kotaskova J, et al
    Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
    Am J Hematol. 2017 Jan 25. doi: 10.1002/ajh.24660.
    PubMed     Text format     Abstract available


  13. JAYAKAR V, Cheung K, Yebra-Fernandez E, Bain BJ, et al
    The distinctive cytological features of T-cell prolymphocytic leukemia.
    Am J Hematol. 2017 Jan 25. doi: 10.1002/ajh.24659.
    PubMed     Text format    


  14. PLUTA A, Robak T, Wrzesien-Kus A, Budziszewska BK, et al
    Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly AML patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
    Am J Hematol. 2017 Jan 19. doi: 10.1002/ajh.24654.
    PubMed     Text format     Abstract available


  15. FUJISAWA S, Mizuta S, Akiyama H, Ueda Y, et al
    Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
    Am J Hematol. 2017 Jan 19. doi: 10.1002/ajh.24653.
    PubMed     Text format     Abstract available


  16. TIRIBELLI M, Geromin A, Damiani D
    Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2017 Jan 11. doi: 10.1002/ajh.24651.
    PubMed     Text format    


  17. WEINBERG OK, Sohani AR, Bhargava P, Nardi V, et al
    Diagnostic Work-up of Acute Myeloid Leukemia.
    Am J Hematol. 2017 Jan 9. doi: 10.1002/ajh.24648.
    PubMed     Text format     Abstract available


  18. GABALLA S, Saliba R, Oran B, Brammer JE, et al
    Relapse Risk and Survival in Patients with FLT3 Acute Myeloid Leukemia Undergoing Stem Cell Transplantation.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24632.
    PubMed     Text format     Abstract available


  19. PEMMARAJU N, Kantarjian H, Jorgensen JL, Jabbour E, et al
    Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24629.
    PubMed     Text format     Abstract available


  20. CANAANI J, Beohou E, Labopin M, Socie G, et al
    Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT.
    Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24640.
    PubMed     Text format     Abstract available


    December 2016
  21. WANG W, Wang SA, Medeiros LJ, Khoury JD, et al
    Pure Erythroid Leukemia.
    Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24626.
    PubMed     Text format     Abstract available


  22. SHORT NJ, Kantarjian HM, Sasaki K, Ravandi F, et al
    Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
    Am J Hematol. 2016 Dec 22. doi: 10.1002/ajh.24625.
    PubMed     Text format     Abstract available


    November 2016
  23. PINNIX CC, Chi L, Jabbour EJ, Milgrom SA, et al
    Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia.
    Am J Hematol. 2016 Nov 22. doi: 10.1002/ajh.24611.
    PubMed     Text format     Abstract available


  24. ALDOSS I, Stiller T, Song J, AlMalki M, et al
    Philadelphia chromosome as a recurrent event among therapy-related acute leukemia.
    Am J Hematol. 2016 Nov 10. doi: 10.1002/ajh.24604.
    PubMed     Text format    


  25. WINESTONE LE, Getz KD, Miller TP, Wilkes JJ, et al
    The Role of Acuity of Illness at Presentation in Early Mortality in Black Children with Acute Myeloid Leukemia.
    Am J Hematol. 2016 Nov 10. doi: 10.1002/ajh.24605.
    PubMed     Text format     Abstract available


  26. BAIN BJ
    Early leukemic transformation of adult T-cell leukemia/lymphoma presenting as meningeal lymphoma.
    Am J Hematol. 2016 Nov 8. doi: 10.1002/ajh.24602.
    PubMed     Text format    


  27. SAYAR H, Bashardoust P, Cripe L, Chakraborty S, et al
    Long-term outcome of NPM1 mutated acute myeloid leukemia: A single-institution experience.
    Am J Hematol. 2016 Nov 4. doi: 10.1002/ajh.24601.
    PubMed     Text format    


    October 2016
  28. CASTAGNETTI F, Di Raimondo F, De Vivo A, Spitaleri A, et al
    A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
    Am J Hematol. 2016 Oct 22. doi: 10.1002/ajh.24591.
    PubMed     Text format     Abstract available


  29. NABHAN C, Mato AR, Feinberg BA
    Clinical Pathways in Chronic lymphocytic Leukemia: Challenges and Solutions.
    Am J Hematol. 2016 Oct 20. doi: 10.1002/ajh.24589.
    PubMed     Text format    


  30. RAESS PW, Cascio MJ, Fan G, Press R, et al
    Concurrent STAT3, DNMT3A and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential.
    Am J Hematol. 2016 Oct 19. doi: 10.1002/ajh.24586.
    PubMed     Text format    


  31. GREENER D, Henrichs KF, Liesveld JL, Heal JM, et al
    Improved Outcomes in Acute Myeloid Leukemia Patients Treated with Washed Transfusions.
    Am J Hematol. 2016 Oct 19. doi: 10.1002/ajh.24585.
    PubMed     Text format    


  32. PATNAIK MM, Barraco D, Lasho TL, Finke CM, et al
    DNMT3A Mutations are Associated with Inferior Overall and Leukemia-free Survival in Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2016 Oct 12. doi: 10.1002/ajh.24581.
    PubMed     Text format     Abstract available


  33. HU Z, Sun Y, Wang W, Medeiros LJ, et al
    Refractory Hairy Cell Leukemia-Variant.
    Am J Hematol. 2016 Oct 11. doi: 10.1002/ajh.24580.
    PubMed     Text format    


  34. ROSKO A, Wang HL, de Lima M, Sandmaier B, et al
    Reduced Intensity Conditioned Allograft Yields Favorable Survival for Older Adults with B-cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2016 Oct 6. doi: 10.1002/ajh.24575.
    PubMed     Text format     Abstract available


    September 2016
  35. LI R, Hu X, Wang L, Cheng H, et al
    Fludarabine and Cytarabine versus High-dose Cytarabine in Consolidation Treatment of t(8; 21) Acute Myeloid Leukemia: a prospective, randomized study.
    Am J Hematol. 2016 Sep 27. doi: 10.1002/ajh.24569.
    PubMed     Text format     Abstract available


  36. EDER S, Beohou E, Labopin M, Sanz J, et al
    Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia - a survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Am J Hematol. 2016 Sep 27. doi: 10.1002/ajh.24567.
    PubMed     Text format     Abstract available



  37. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia.
    Am J Hematol. 2016;91:965.
    PubMed     Text format    


    August 2016
  38. CORTES JE, Khoury HJ, Kantarjian HM, Lipton JH, et al
    Long-term Bosutinib For Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib Plus Dasatinib and/or Nilotinib.
    Am J Hematol. 2016 Aug 17. doi: 10.1002/ajh.24536.
    PubMed     Text format     Abstract available


  39. ESTEY E
    Acute myeloid leukemia: 2016 Update on risk-stratification and management.
    Am J Hematol. 2016;91:824-46.
    PubMed     Text format     Abstract available


    July 2016
  40. KUMAR AJ, Gimotty PA, Gelfand J, Buck G, et al
    Delays in Post-Remission Chemotherapy for Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia are Associated with Inferior Outcomes in Patients who Undergo Allogeneic Transplant: An Analysis from ECOG 2993/MRC UK ALLXII.
    Am J Hematol. 2016 Jul 28. doi: 10.1002/ajh.24497.
    PubMed     Text format     Abstract available


  41. JAIN P, Kanagal-Shamanna R, Wierda W, Keating M, et al
    Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.
    Am J Hematol. 2016 Jul 28. doi: 10.1002/ajh.24496.
    PubMed     Text format    


  42. MOLICA S, Shanafelt TD, Giannarelli D, Gentile M, et al
    The chronic lymphocytic leukemia international prognostic index (CLL-IPI) predicts time to first treatment in early CLL: Independent Validation in a Prospective Cohort of Early Stage Patients.
    Am J Hematol. 2016 Jul 27. doi: 10.1002/ajh.24493.
    PubMed     Text format     Abstract available


  43. AGBAY RL, Jain N, Loghavi S, Medeiros LJ, et al
    Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Am J Hematol. 2016 Jul 14. doi: 10.1002/ajh.24473.
    PubMed     Text format     Abstract available


  44. FLINN IW, Ruppert AS, Harwin W, Waterhouse D, et al
    A Phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia (CLL).
    Am J Hematol. 2016 Jul 7. doi: 10.1002/ajh.24468.
    PubMed     Text format     Abstract available


    June 2016
  45. DUBUC AM, Davids MS, Pulluqi M, Pulluqi O, et al
    FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated Chronic Lymphocytic Leukemia (CLL).
    Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24452.
    PubMed     Text format     Abstract available


  46. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
    Am J Hematol. 2016;91:631-42.
    PubMed     Text format     Abstract available


  47. KUMAR AJ, Vassilev P, Loren AW, Luger SM, et al
    Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
    Am J Hematol. 2016;91:426-9.
    PubMed     Text format     Abstract available


  48. HAMILTON BK, Visconte V, Jia X, Tabarroki A, et al
    Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.
    Am J Hematol. 2016;91:406-9.
    PubMed     Text format     Abstract available


  49. CUNNINGHAM I, Kohno B
    18 FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases.
    Am J Hematol. 2016;91:379-84.
    PubMed     Text format     Abstract available


    May 2016
  50. SHAH NP, Rousselot P, Schiffer C, Rea D, et al
    Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
    Am J Hematol. 2016 May 19. doi: 10.1002/ajh.24423.
    PubMed     Text format     Abstract available


  51. RYTTING ME, Jabbour EJ, Jorgensen JL, Ravandi F, et al
    Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-munster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen.
    Am J Hematol. 2016 May 14. doi: 10.1002/ajh.24419.
    PubMed     Text format     Abstract available


  52. BADAR T, Handisides DR, Benito JM, Richie MA, et al
    A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia.
    Am J Hematol. 2016 May 11. doi: 10.1002/ajh.24415.
    PubMed     Text format     Abstract available


  53. WOLACH O, Stevenson KE, Wadleigh M, DeAngelo DJ, et al
    Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.
    Am J Hematol. 2016 May 6. doi: 10.1002/ajh.24410.
    PubMed     Text format     Abstract available



  54. Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).
    Am J Hematol. 2016;91:E301.
    PubMed     Text format    


  55. KONUMA T, Tsukada N, Kanda J, Uchida N, et al
    Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.
    Am J Hematol. 2016;91:E284-92.
    PubMed     Text format     Abstract available


  56. ELALA YC, Lasho TL, Gangat N, Finke C, et al
    Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Am J Hematol. 2016;91:503-6.
    PubMed     Text format     Abstract available


  57. KOMROKJI RS, Kulasekararaj A, Al Ali NH, Kordasti S, et al
    Autoimmune diseases and myelodysplastic syndromes.
    Am J Hematol. 2016;91:E280-3.
    PubMed     Text format     Abstract available


  58. CEPPI F, Weitzman S, Woessmann W, Davies K, et al
    Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Am J Hematol. 2016;91:486-91.
    PubMed     Text format     Abstract available


  59. HEXNER EO, Luger SM, Reshef R, Jeschke GR, et al
    Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.
    Am J Hematol. 2016;91:453-60.
    PubMed     Text format     Abstract available


    April 2016
  60. EGAN D, Radich J
    Monitoring Disease Burden in Chronic Myeloid Leukemia: Past, Present, and Future.
    Am J Hematol. 2016 Apr 5. doi: 10.1002/ajh.24381.
    PubMed     Text format     Abstract available


  61. FRIEDMAN DR, Sibley AB, Owzar K, Chaffee KG, et al
    Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: A multi-institutional study.
    Am J Hematol. 2016 Apr 2. doi: 10.1002/ajh.24376.
    PubMed     Text format     Abstract available


    March 2016
  62. NABHAN C, Chaffee KG, Slager SL, Galanina N, et al
    Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia.
    Am J Hematol. 2016 Mar 25. doi: 10.1002/ajh.24374.
    PubMed     Text format     Abstract available


  63. GUGLIOTTA G, Castagnetti F, Breccia M, Gozzini A, et al
    Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
    Am J Hematol. 2016 Mar 11. doi: 10.1002/ajh.24362.
    PubMed     Text format     Abstract available


  64. CHANTEPIE SP, Parienti JJ, Salaun V, Benabed K, et al
    The prognostic value of hematogones in patients with acute myeloid leukemia.
    Am J Hematol. 2016 Mar 2. doi: 10.1002/ajh.24350.
    PubMed     Text format     Abstract available


  65. BERNARDI M, Carrabba M, Messina C, Milani R, et al
    Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs.
    Am J Hematol. 2016 Mar 1. doi: 10.1002/ajh.24345.
    PubMed     Text format    


  66. SEFTEL MD, Neuberg D, Zhang MJ, Wang HL, et al
    Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.
    Am J Hematol. 2016;91:322-9.
    PubMed     Text format     Abstract available


  67. PATNAIK MM, Lasho TL, Finke CM, Pardanani A, et al
    Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis.
    Am J Hematol. 2016;91:E12-4.
    PubMed     Text format    


  68. DEOTARE U, Yee KW, Le LW, Porwit A, et al
    Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.
    Am J Hematol. 2016;91:283-6.
    PubMed     Text format     Abstract available


    February 2016
  69. PANERO J, Alves-Paiva RM, Roisman A, Santana-Lemos BA, et al
    Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
    Am J Hematol. 2016 Feb 6. doi: 10.1002/ajh.24324.
    PubMed     Text format     Abstract available


  70. JABBOUR E, Kantarjian H
    Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Am J Hematol. 2016;91:252-265.
    PubMed     Text format     Abstract available


  71. DINARDO CD, Garcia-Manero G, Pierce S, Nazha A, et al
    Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Am J Hematol. 2016;91:227-232.
    PubMed     Text format     Abstract available


  72. TAVITIAN S, Denis A, Vergez F, Berard E, et al
    Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.
    Am J Hematol. 2016;91:193-8.
    PubMed     Text format     Abstract available


    January 2016
  73. BERNASCONI P, Farina M, Boni M, Dambruoso I, et al
    Therapeutically targeting self-reinforcing leukemic niches in acute myeloid leukemia (AML): A worthy endeavour?
    Am J Hematol. 2016 Jan 28. doi: 10.1002/ajh.24312.
    PubMed     Text format     Abstract available


  74. ROOS-WEIL D, Nguyen-Khac F, Bernard OA
    Chronic lymphocytic leukemia: Time to go past genomics?
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24301.
    PubMed     Text format     Abstract available


  75. WU B, Harrison G, Wang E
    "Hairy" cells in acute promyelocytic leukemia: Excess myeloperoxidase with formation of needle-shaped crystalline projections on the cytochemical stain in a case with variant morphology.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24298.
    PubMed     Text format    


  76. SALE S, Fumi M, Pancione Y, Parente D, et al
    The fortuitous diagnosis of Burkitt lymphoma in a patient with chronic myelomonocytic leukemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24297.
    PubMed     Text format    


  77. VITALE C, Jabbour E, Lu X, Yabe M, et al
    Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia.
    Am J Hematol. 2016 Jan 22. doi: 10.1002/ajh.24302.
    PubMed     Text format    


  78. SHORT NJ, Kantarjian HM, Jabbour EJ, O'Brien SM, et al
    Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.
    Am J Hematol. 2016 Jan 21. doi: 10.1002/ajh.24296.
    PubMed     Text format     Abstract available


  79. JAIN P, Tang G, Huh YO, Yin CC, et al
    Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation.
    Am J Hematol. 2016 Jan 21. doi: 10.1002/ajh.24295.
    PubMed     Text format    


  80. FORDHAM NJ, Stern S, Swansbury J, Bain BJ, et al
    The distinctive micromegakaryocytes of transformed chronic myeloid leukemia.
    Am J Hematol. 2016 Jan 9. doi: 10.1002/ajh.24290.
    PubMed     Text format    


  81. JABBOUR E
    Chronic myeloid leukemia: First-line drug of choice.
    Am J Hematol. 2016;91:59-66.
    PubMed     Text format     Abstract available


  82. FREY NV, Porter DL
    CAR T-cells merge into the fast lane of cancer care.
    Am J Hematol. 2016;91:146-50.
    PubMed     Text format     Abstract available


  83. TEFFERI A
    Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Am J Hematol. 2016;91:50-8.
    PubMed     Text format     Abstract available


    December 2015
  84. MANGARU Z, Shetty S, Visconte V, Liu HD, et al
    Acute myeloid leukemia with inv(16)(p13.1q22), abnormal eosinophils, and absence of peripheral blood and bone marrow blasts.
    Am J Hematol. 2015 Dec 30. doi: 10.1002/ajh.24289.
    PubMed     Text format    


  85. ELLIOTT MA, Tefferi A
    Chronic Neutrophilic Leukemia 2016: Update on diagnosis, molecular genetics, prognosis and management.
    Am J Hematol. 2015 Dec 23. doi: 10.1002/ajh.24284.
    PubMed     Text format     Abstract available


  86. RAI KR, Jain P
    Chronic lymphocytic leukemia (CLL) - Then and Now.
    Am J Hematol. 2015 Dec 21. doi: 10.1002/ajh.24282.
    PubMed     Text format     Abstract available


  87. CAMPUZANO-ZULUAGA G, Deutsch Y, Salzberg M, Gomez A, et al
    Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24271.
    PubMed     Text format     Abstract available


  88. AOKI J, Kanamori H, Tanaka M, Yamasaki S, et al
    Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24270.
    PubMed     Text format     Abstract available


  89. YU H, Wertheim G, Shankar S, Paessler M, et al
    Marked eosinophilia masking B lymphoblastic leukemia.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24266.
    PubMed     Text format    


  90. ZENT CS, Wang XV, Ketterling RP, Hanson CA, et al
    A Phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A Trial of the ECOG-ACRIN Cancer Research Group (E1908).
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24265.
    PubMed     Text format     Abstract available


  91. MOLLER T, Moser C, Adamsen L, Rugaard G, et al
    Early warning and prevention of pneumonia in acute leukemia by patient education, spirometry, and positive expiratory pressure: A randomized controlled trial.
    Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24262.
    PubMed     Text format     Abstract available


    November 2015
  92. KANTARJIAN H
    Acute Myeloid Leukemia- Major Progress over Four Decades, and Glimpses into the Future.
    Am J Hematol. 2015 Nov 24. doi: 10.1002/ajh.24246.
    PubMed     Text format    


  93. GAMBACORTI-PASSERINI C, Aroldi A, Cordani N, Piazza R, et al
    Chronic myeloid leukemia: Second-line drugs of choice.
    Am J Hematol. 2015 Nov 20. doi: 10.1002/ajh.24247.
    PubMed     Text format     Abstract available


  94. CASTILLO JJ, Mulkey F, Geyer S, Kolitz JE, et al
    Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials.
    Am J Hematol. 2015 Nov 3. doi: 10.1002/ajh.24230.
    PubMed     Text format     Abstract available


  95. SHAH NP, Wallis N, Farber HW, Mauro MJ, et al
    Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
    Am J Hematol. 2015;90:1060-4.
    PubMed     Text format     Abstract available


    October 2015
  96. PALOMO L, Xicoy B, Garcia O, Mallo M, et al
    Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.
    Am J Hematol. 2015 Oct 28. doi: 10.1002/ajh.24227.
    PubMed     Text format     Abstract available


  97. KEKRE N, Ho VT
    Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis and Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2015 Oct 9. doi: 10.1002/ajh.24215.
    PubMed     Text format     Abstract available


  98. JAIN P, Guilin T, Konoplev SN, Kanagal-Shamanna R, et al
    Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
    Am J Hematol. 2015 Oct 6. doi: 10.1002/ajh.24208.
    PubMed     Text format    


  99. OFRAN Y, Leiba R, Ganzel C, Saban R, et al
    Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia.
    Am J Hematol. 2015 Oct 5. doi: 10.1002/ajh.24207.
    PubMed     Text format     Abstract available


  100. MORI S, Vagge E, le Coutre P, Abruzzese E, et al
    Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
    Am J Hematol. 2015;90:910-4.
    PubMed     Text format     Abstract available


    September 2015
  101. GARCIA-MANERO G
    Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Am J Hematol. 2015;90:831-41.
    PubMed     Text format     Abstract available


    August 2015
  102. LING VY, Lee D, McQuilten Z, Avery S, et al
    Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2015 Aug 28. doi: 10.1002/ajh.24179.
    PubMed     Text format    


  103. BADAR T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, et al
    Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
    Am J Hematol. 2015 Aug 24. doi: 10.1002/ajh.24140.
    PubMed     Text format     Abstract available


  104. VITALE C, Lu X, Abderrahman B, Takahashi K, et al
    t(9;22) as secondary alteration in core-binding factor de novo acute myeloid leukemia.
    Am J Hematol. 2015 Aug 7. doi: 10.1002/ajh.24143.
    PubMed     Text format    


  105. CAME N, Westerman D, Juneja S
    The denominator variable in the quantitation of MRD in acute myeloid leukemia.
    Am J Hematol. 2015 Aug 6. doi: 10.1002/ajh.24142.
    PubMed     Text format    


  106. DINARDO CD, Ravandi F, Agresta S, Konopleva M, et al
    Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
    Am J Hematol. 2015;90:732-6.
    PubMed     Text format     Abstract available


  107. LIM SJ, Lim MJ, Raptis A, Hou JZ, et al
    Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
    Am J Hematol. 2015;90:715-8.
    PubMed     Text format     Abstract available


    July 2015
  108. LIM SN, Joo YD, Lee KH, Kim DY, et al
    Long-term follow-up of imatinib plus combination chemotherapy in for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Am J Hematol. 2015 Jul 30. doi: 10.1002/ajh.24137.
    PubMed     Text format     Abstract available


  109. XU Y, Sun Y, Shen H, Ding L, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Am J Hematol. 2015 Jul 29. doi: 10.1002/ajh.24135.
    PubMed     Text format     Abstract available


  110. COUTURIER MA, Huguet F, Chevallier P, Suarez F, et al
    Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with L-asparaginase: The GRAALL experience.
    Am J Hematol. 2015 Jul 27. doi: 10.1002/ajh.24130.
    PubMed     Text format     Abstract available


  111. STEPHENS DM, Ruppert AS, Weirda WG, Jones JA, et al
    Externally Validated Predictive Clinical Model for Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients.
    Am J Hematol. 2015 Jul 22. doi: 10.1002/ajh.24125.
    PubMed     Text format     Abstract available


  112. SCIUME M, Vincenti D, Reda G, Orofino N, et al
    Low-dose Alemtuzumab in Refractory/Relapsed Chronic Lymphocytic Leukemia: Genetic Profile and Long-term Outcome from a Single Center Experience.
    Am J Hematol. 2015 Jul 22. doi: 10.1002/ajh.24127.
    PubMed     Text format     Abstract available


  113. GROSICKI S, Holowiecki J, Kuliczkowski K, Skotnicki A, et al
    Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients; a retrospective, multicenter Polish Adult Leukemia Group study.
    Am J Hematol. 2015 Jul 6. doi: 10.1002/ajh.24113.
    PubMed     Text format     Abstract available


  114. BAIN BJ, Chakravorty S, Ancliff P
    Congenital acute megakaryoblastic leukemia.
    Am J Hematol. 2015 Jul 6. doi: 10.1002/ajh.24109.
    PubMed     Text format    


  115. TANG G, Fu B, Hu S, Lu X, et al
    Prognostic Impact of Acquisition of Cytogenetic Abnormalities during the Course of Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2015 Jul 6. doi: 10.1002/ajh.24108.
    PubMed     Text format     Abstract available


  116. ARMITAGE JO
    The aggressive peripheral T-cell lymphomas: 2015.
    Am J Hematol. 2015;90:665-73.
    PubMed     Text format     Abstract available


  117. BRAYER J, Lancet JE, Powers J, List A, et al
    WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
    Am J Hematol. 2015;90:602-7.
    PubMed     Text format     Abstract available


    June 2015
  118. BRECCIA M, De Propris MS, Molica M, Colafigli G, et al
    Introducing Biological Features at Diagnosis Improves the Relapse Risk Stratification in Patients with Acute Promyelocytic Leukemia Treated with Atra and Chemotherapy.
    Am J Hematol. 2015 Jun 25. doi: 10.1002/ajh.24033.
    PubMed     Text format    


  119. WANQUET A, Prebet T, Berthon C, Sebert M, et al
    Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
    Am J Hematol. 2015 Jun 25. doi: 10.1002/ajh.24099.
    PubMed     Text format     Abstract available


  120. IRIYAMA N, Fujisawa S, Yoshida C, Wakita H, et al
    Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: Results of the D-First study.
    Am J Hematol. 2015 Jun 23. doi: 10.1002/ajh.24096.
    PubMed     Text format     Abstract available


  121. VOSE JM
    Mantle Cell Lymphoma: 2015 Update on Diagnosis, Risk-Stratification and Clinical Management.
    Am J Hematol. 2015 Jun 23. doi: 10.1002/ajh.24094.
    PubMed     Text format     Abstract available


  122. GRIFFIN PT, Komrokji RS, DeCastro CM, Rizzieri DA, et al
    A multicenter, Phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
    Am J Hematol. 2015 Jun 19. doi: 10.1002/ajh.24087.
    PubMed     Text format     Abstract available


  123. LAZAREVIC V, Rosso A, Juliusson G, Antunovic P, et al
    Prognostic significance of high hyperdiploid and tri-/tetraploid adult acute myeloid leukemia.
    Am J Hematol. 2015 Jun 19. doi: 10.1002/ajh.24091.
    PubMed     Text format     Abstract available


  124. HUNAULT-BERGER M, Leguay T, Huguet F, Lepretre S, et al
    A phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 Study.
    Am J Hematol. 2015 Jun 19. doi: 10.1002/ajh.24093.
    PubMed     Text format     Abstract available


  125. AL-HAMADANI M, Habermann TM, Cerhan JR, Macon WR, et al
    Non-Hodgkin lymphoma subtype distribution, geo-demographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998-2011.
    Am J Hematol. 2015 Jun 10. doi: 10.1002/ajh.24086.
    PubMed     Text format     Abstract available


  126. DAMIANI D, Tiribelli M, Geromin A, Michelutti A, et al
    ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome.
    Am J Hematol. 2015 Jun 9. doi: 10.1002/ajh.24084.
    PubMed     Text format     Abstract available


  127. GAMBACORTI-PASSERINI C, Kantarjian HM, Kim DW, Khoury HJ, et al
    Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
    Am J Hematol. 2015 Jun 1. doi: 10.1002/ajh.24034.
    PubMed     Text format     Abstract available


  128. BAIRD JH, Birnbaum BK, Porter DL, Frey NV, et al
    Voriconazole-induced periostitis after allogeneic stem cell transplantation.
    Am J Hematol. 2015;90:574-5.
    PubMed     Text format    


    May 2015
  129. BADAR T, Shetty A, Bueso-Ramos C, Cortes J, et al
    Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
    Am J Hematol. 2015 May 27. doi: 10.1002/ajh.24074.
    PubMed     Text format     Abstract available


  130. POIRE X, Labopin M, Cornelissen JJ, Volin L, et al
    Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the Acute Leukemia Working Party (ALWP) of the European group of Blood and Marrow Transplantation (EBMT).
    Am J Hematol. 2015 May 25. doi: 10.1002/ajh.24069.
    PubMed     Text format     Abstract available


  131. SCHIAVINATO A, Piva E, Pantano G, Cornoldi P, et al
    A case of eosinophilic disorder that evolved in acute lymphoblastyc leukemia.
    Am J Hematol. 2015 May 11. doi: 10.1002/ajh.24048.
    PubMed     Text format    


  132. CHEN Z, Wang W, Rich A, Tang G, et al
    Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
    Am J Hematol. 2015 May 11. doi: 10.1002/ajh.24045.
    PubMed     Text format    


  133. GIFFORD G, Wong K, Kerridge I, Stevenson W, et al
    Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
    Am J Hematol. 2015;90:E97-100.
    PubMed     Text format    


  134. FIANCHI L, Pagano L, Piciocchi A, Candoni A, et al
    Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias.
    Am J Hematol. 2015;90:E80-5.
    PubMed     Text format     Abstract available


  135. HAMAD N, Shanavas M, Michelis FV, Uhm J, et al
    Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Am J Hematol. 2015;90:392-9.
    PubMed     Text format     Abstract available


    April 2015
  136. CORTES J, Mauro M, Steegmann JL, Saglio G, et al
    Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
    Am J Hematol. 2015;90:E66-72.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: